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Acronyms 
 
CATI   Computer Assisted Telephone Interview 
ECDC    European Centre for Disease Prevention and Control 
ECOS    Em Casa Observamos Saúde 
HC    Health Centre 
I-MOVE    Influenza Monitoring Vaccine Effectiveness 
IPD    Invasive Pneumococcal Disease  
IVE    Influenza Vaccine Effectiveness 
OR    Odds Ratio 
PCV13      13-valent Pneumococcal Conjugated Vaccine  
PP     Pneumococcal Pneumonia 
PPSV23    Pneumococcal Polysaccharide Vaccine  
TND    Test-negative Design 
VC    Vaccination Coverage 
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1. Background 
Vaccination has been one of the main measures to mitigate influenza impacts and its role in reducing 
the risk of influenza infection and some of its complications is well known (1).  
Influenza viruses can induce pneumonia and also favour bacterial co-infections and secondary 
bacterial infections. The pathogenic mechanism is multifactorial involving host susceptibility and 
transmission between close contacts, respiratory epithelial damage, changes in airway functions with 
up-regulation/exposure of specific receptors; or increased level of proinflammatory cytokines and 
vascular permeability of the pulmonary tract allowing bacterial invasion of the blood (2-6). While 
these mechanisms could favor supra-infections with other bacteria, pneumococci exhibit a special 
synergism with influenza and other respiratory viruses. First, the increase in carriage prevalence 
during the winter season concurs with the circulation of influenza and other respiratory viruses (7,8) 
mainly due to increased pneumococcal acquisition (9) and density in nasopharynx (10). Second, the 
incidence and severity of pneumococcal pneumonia (PP) increase during the winter season (5), being 
the invasiveness of pneumococcal serotypes mainly related to the carriage density and acquisition. 
As consequence, there is plausibility that influenza vaccination may also protect against 
pneumococcal outcomes.  
In Portugal, individuals with 65 years of age and more are part of the target group for influenza 
vaccination (11). Data from the vaccine coverage monitoring system indicates that vaccination 
coverage in elderly has been approximately 50% (12). Since 2012, influenza vaccination is offered 
free of charge to the elderly ( ≥ 65 years) at the National Health System without prescription. 
Individuals can also be vaccinated in a pharmacy if the person has a medical prescription. During the 
2015/16 season around 75% of the vaccinated elderly received the vaccine in their Health Centre 
(HC) (14). This percentage varied between heath regions and in Lisbon (reference population of this 
study) only 68% of elderly referred been vaccinated in their HC (unpublished data). Each season, 
Portuguese national influenza vaccination campaign starts in October (14) and most elderly were 
vaccinated before the end of December (15).  
Portugal, alongside with other European countries has been using the screening method to estimate 
seasonal influenza vaccine effectiveness (IVE). This method was first used in the 2009/10 season and 
was implemented during the following three seasons. The results obtained from its study design, 
when compared to the test-negative design, were less precise and more likely to be biased (16).  
According to Orenstein et al (17), the screening method only provides a rough guide of the VE point 
estimates and for this reason, it should not be relied upon for precise estimates. Nevertheless, it can 
be used to easily monitor VE, given its potential advantage in terms of timeliness and low resources 
needs.  We  considered the screening method as a potential design to pilot within the I-MOVE+ to 
estimate the influenza vaccine effectiveness against two specific outcomes: Invasive Pneumococcal 
Disease (IPD) and PP.  
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The aim of this study was to evaluate the feasibility of using the screening method to estimate the 
influenza vaccine effectiveness against IPD and PP using hospital and surveillance data. 
 
2. Objective 
The main objective was to measure in the community dwelling elderly population (aged ≥65 years) 
the direct effect (effectiveness) of influenza vaccine against:  
i. Pneumococcal pneumonia (PP); 
ii. Invasive pneumococcal disease (IPD). 
3. Methods 
3.1 Study design 
Screening method that compares the proportion of cases who were vaccinated (Cases) with the 
proportion vaccinated in the population from where cases have arose (Study reference population). 
3.2 Study population 
The study population consisted of the community dwelling individuals aged ≥65 years old 
hospitalized in two central hospitals in Lisbon (Centro Hospitalar Lisboa Norte and Centro Hospitalar 
Lisboa Central) during the study period.   
Given that hospitals enrolled in this study are located in Lisbon the reference population 
corresponded to the non-institutionalized population resident in Lisbon region. 
3.3 Study period 
Cases From week 40/2016 to week 25/2018 
Reference population (ECOS sample) From week 11/2016 to week 19/2016 
 
Only cases admitted to participating hospitals at least 14 days after the beginning of the vaccination 
campaign during influenza circulation period (week 42/2016 to week 20/2017; 43/2017 to week 
19/2018) were considered. 
3.4 Outcomes 
Outcomes of interest were PP and IPD as defined below. 
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3.5 Definitions 
Pneumococcal Pneumonia Case 
A PP case was defined as a hospitalized individual (more than 24 hours) with pneumonia that had a 
positive sample (urine, blood, sputum, other) for Streptococcus pneumoniae.  
IPD cases were defined as a hospitalized individual (more than 24 hours) that had a positive result for 
Streptococcus pneumoniae from a sterile fluid.   
Reference Population 
Reference population data were obtained from a sample of approximately 1000 households 
stratified by region selected from a dual sampling frame – using random digit dialing mobile and 
landline phones (ECOS sample) (13). This study has been monitoring the vaccine coverage in 
mainland Portuguese population since 1998 (18,19). 
 
3.6 Sampling 
Case identification 
Cases were identified from two hospitals using two different strategies. For one hospital (Centro 
Hospitalar Lisboa Norte), PP cases were identified from the hospital discharge database. All patients 
that had a hospitalization episode which primary diagnosis was coded as 481,486 (pneumococcal 
pneumonia and  unspecified pneumonia) and 510 (empyema) were selected. Medical records from 
all patients were reviewed by a medical doctor to identify possible exclusion criteria and to confirm 
laboratorial results. Data collection was performed using a standard paper form.  
Regarding to the other hospital (Centro Hospitalar Lisboa Central), PP cases were selected among 
Severe Acute Respiratory Infection (SARI) patients enrolled for EVA hospital Study (20). SARI cases 
were considered as PP cases if they had a chest X-Ray compatible with pneumonia and a positive 
urinary antigenic test (or hemoculture) for Streptococcus pneumoniae (Annex 1).  
 
Case exclusion criteria 
Cases were excluded if  they:  
 were institutionalized; 
 were admitted to the hospital out of the influenza circulation period; 
 had registry of nosocomial infection; 
 were not resident in Lisbon Region; 
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 didn’t have registry of Streptococcus pneumoniae infection laboratorial confirmed; 
 were vaccinated against seasonal influenza less than 15 days before the admission. 
 
3.7 Exposure (Vaccination) 
Vaccination status definition for cases 
Cases were considered as vaccinated against influenza if they were vaccinated in the respective 
season until 14 days before hospitalization. 
Ascertainment of vaccination in cases 
Ascertainment was made using medical and vaccination registries. The vaccination history included 
date of administration (when available). Data collection was performed by a medical doctor through 
consultation of hospital and vaccination registries. 
Vaccination coverage in reference group 
The vaccine coverage in the study reference population was collected using the ECOS sample. In each 
interviewed household, one individual aged 18 or more years old provided information on his/her 
vaccination status and on the vaccination status of the rest of the household elements. For validation 
purposes, individuals were asked if the inoculation was through a “shot”. The vaccination history 
included month of administration. 
3.8 Other variables collected  
 
Chronic conditions 
Cases were considered as being chronically ill if two or more chronic conditions (cardiovascular 
disease, chronicle respiratory disease, oncological and hematological diseases, other immune 
deficiency conditions) were registered in the hospital records.  
For the ECOS sample individuals were also considered as being chronically ill if they reported had 
been diagnosed (by a health professional) with at least two of the conditions included in the 
interview questionnaires (13). 
 
Pneumococcal vaccines 
Pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal conjugated vaccine 
(PCV13) uptake was also collected only for cases using medical records and vaccination registry. 
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Smoking and alcohol  
Smoking and alcohol abuse were collected only for cases using medical records. 
3.9 Source of information  
           Table 1: Summary of data sources for cases and for reference population 
 
3.10 Data collected, management and validation 
Full description of data collected, management and validation was described elsewhere for ECOS 
sample (13). A summary of collected  data is presented in Table 2 and data dictionary of variables 
collected for cases  is presented in Annex 2. 
Table 2: Summary of data collected, management and validation in cases and in the reference population (ECOS sample). 
 Cases Reference population 
D
at
a 
co
lle
ct
e
d
 
• Sociodemographic data (sex, age), 
• Influenza vaccination status in the 
season, 
• Smoking history,  
• Alcohol abuse, 
• Chronic conditions,  
• PCV13, PPSV23 vaccination status 
• Laboratorial results, 
Data collected was performed using a 
standardized paper form 
• Sociodemographic data (sex, age), 
• Chronic conditions, 
• Influenza vaccine uptake 2015/16 
season,  
• Intention of being vaccinated next 
season 
D
at
a 
m
an
ag
e
m
e
n
t 
Data entry was performed on a Microsoft Excel 
Database by typing in the answers from the 
paper form. 
CATI survey was conducted and the database was 
validated and analyzed by the Department of 
Epidemiology at INSA. 
D
at
a 
va
lid
at
io
n
 
All cases were checked for missing values and 
inconsistencies. Data clarification and 
information recovery was made through 
medical registries checking. 
Database validation was performed for each 
variable trough the identification of impossible 
values and inconsistencies identification. These 
inconsistencies were validated with the 
interviewer and/or with the participant via a new 
phone contact. 
Notes: PPSV23: pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugated vaccine; CATI: 
Computer assisted telephone interview; INSA: Instituto Nacional de Saúde Doutor Ricardo Jorge 
 
Study 
Standardised 
questionnaire 
Laboratory results Patient medical records Vaccination status 
Cases No Yes Yes Registry 
Reference 
population 
Yes No No Self report/proxy 
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3.11 Statistical Analysis 
Descriptive analysis 
Cases and the study reference population were described by demographic characteristics and 
vaccination status.  
Given its complex sample nature, design adjusted Rao–Scott version of Pearson’s chi-square was 
used for association studies in the ECOS sample (21).  
Measure of effect  
IVE was estimated by comparing the proportion of vaccinated PP cases to the vaccine coverage in the 
study reference population using the Orenstein formula (22):  
𝑉𝐸 =
𝑃𝑃𝑉 − 𝑃𝐶𝑉
𝑃𝑃𝑉(1 − 𝑃𝐶𝑉)
 
in which PPV is the vaccine coverage in the reference population, and PCV is the vaccine coverage 
among Cases. Ninety five percent confidence intervals (95%CI) for IVE were computed using the 
Farrington method (23).  
Stratified analysis  
Analysis was stratified according to the availability of vaccination coverage in the reference group: 
 Age groups (65-79 years and ≥80 years); 
 Chronic conditions (< 2 chronic conditions and ≥ 2 chronic conditions). 
 
Statistical analysis was performed using STATA version 13.  
 
3.12 Ethical issues and data protection 
ECOS panel was authorized by the National Data Protection Committee. Data collection regarding to 
cases were approved by the Ethical Committee of the National Institute of Health. 
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4. Results 
4.1 Vaccination coverage in the reference population 
According to the results of ECOS survey (24,25), the vaccine coverage in 2015/16 season for the 
Portuguese population aged 65 years or more was 50.1% (95%CI: 42.1-58.1) (13).  
The majority of the individuals were vaccinated at the HC (60.4%; 95%CI: 49.1%; 70.6%) and during 
October (58.4%; 95%CI: 49.1%; 67.0%). Restricting to our reference population (Lisbon), the 
percentage of vaccinated at the HC was 68.0%. Vaccine coverage for the elderly population shown in 
table 3 revealed no statistically significant differences between regions. 
           Table 3: Influenza vaccine coverage (%) in the Portuguese mainland population and region 
 % 95%CI  p-value* 
North 44.4 (27.5; 62.6) 
0.4374 
Centre 53.1 (39.8; 66.0) 
Lisbon (study reference population) 52.3 (37.6; 66.6) 
Alentejo 51.7 (39.9; 63.3) 
Algarve 55.7 (44.4; 66.5) 
Portugal Mainland 50.1 (42.1; 58.1)  
* design-adjusted Rao–Scott version of Pearson’s chi-square 
4.2 Description of cases 
Given the sampling strategy used, all selected cases had a pneumonia presentation some of them PP 
had a positive hemoculture for Streptococcus pneumonia being possible to classify as IPD. However, 
given the number of cases, PP cases considered in this analysis included invasive and non-invasive 
pneumonia. 
Of 41 PP cases enrolled, 8 (19.5%) met at least one exclusion criteria, and the final sample of cases 
comprised 33 individuals. In all cases, laboratorial tests were performed for etiological diagnosis 
(urinary Streptococcus pneumoniae antigens identification, hemoculture, sputum culture or 
bronchoalveolar lavage culture).  
Table 4 presents the description of selected PP cases. Comparing to the reference population, cases 
had a higher percentage of males and had a higher percentage of individuals chronically ill. Vaccine 
coverage was higher among the reference population.  
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   Table 4: Description of pneumococcal pneumonia cases and Reference population 
 PP Reference Population  
Age, mean (N) 75.8 (33)  75.6 (73.7; 77.6) 
65-79 years, % (n/N) 63.6 (21/33) 72.1 (56.4; 83.8) 
≥80 years, % (n/N) 36.4 (12/33) 27.9 (16.2; 43.6) 
Sex, male %  (n/N) 42.4 (14/33) 36.7 (29.4; 44.6) 
Smokers, %  (n/N) 45.0 (9/20) NA 
Alcohol abuse, %  (n/N) 16.7 (1/6) NA 
≥ 2 chronic conditions , % (n/N) 75.8 (25/31) 45.3 (31.5; 59.9) 
   
Seasonal influenza vaccine, % (n/N) 36.4 (12/33) 52.3 (37.6; 66.6) 
PPSV23, % (n/N) 16.7 (5/30) NA 
PCV13, % (n/N) 9.7  (3/31) NA 
Notes: PP: pneumococcal pneumonia; NA: not available; PPSV23: pneumococcal polysaccharide vaccine;  
PCV13: 13-valent pneumococcal conjugated vaccine 
 
 
4.3 Vaccine coverage  
Overall VC in the reference population was higher than in cases indicating a potential protective 
effect of the influenza vaccine against PP (36.4% vs 52.3%) (Table 5).  
Crude IVE estimate was 47.9% (95%CI: -5.9%; 74.4%) against PP. As no data on PPSV23 and PCV13 
was available for the reference population, restricting analysis to those unvaccinated against 
Streptococcus pneumoniae was not possible. 
Table 5: Influenza vaccine coverage and effectiveness (%) in the study reference population and in pneumococcal pneumonia cases  
 
PP 
(v/n)* 
Reference Population [95%CI] 
Vaccine coverage (%) 36.4 12/33 
52.3 
[37.6;66.6] 
Vaccine effectiveness 47.9 [-5.9; 74.4]  
 
  
 
Vaccine coverage (%) 
65-79 years 38.1 8/21 
49.0 
[33.0; 65.3] 
Vaccine coverage (%) 
≥80 years 33.3 4/12 
60.7 
[30.2; 84.7] 
Vaccine coverage (%) 
<2 chronic conditions 37.5 3/8 
41.6 
[22.6; 63.5] 
Vaccine coverage (%) 
≥ 2 chronic conditions 36.0 9/25 
65.2 
[45.8; 80.5] 
Notes: PP: pneumococcal pneumonia; *vaccinated/total of cases 
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5. Discussion 
 
According to the screening method results, crude influenza vaccine effectiveness against 
pneumococcal pneumonia in hospital settings in 2016/17 and 2017/18 seasons was 47.9% (95%CI: -
5.9%; 74.4%). The point estimate value is higher that reported in other study (31.7%; CI: 0.6% to 
53.1%), but our results had low precision and were not statistically significant (26). 
Given the low to moderate IVE against influenza estimated in the studied seasons, using the test 
negative design the screening method as well (27,28), we consider not plausible such high IVE 
against PP.  But, it may indicate some level of protection of the influenza vaccine against 
pneumococcal pneumonia, which is in line with the hypothesis of risk of bacterial co-infections or 
secondary infections after an Influenza infection. Pneumococci synergism with Influenza and other 
respiratory viruses is well known, being mediated by the increase in pneumococcal acquisition (9) 
and density in nasopharynx (10) during the circulation of influenza and other respiratory viruses.  
However several limitations of the study imposed precautions on results interpretation. Differences 
in chronic conditions and pneumococcal vaccination status between cases and the reference 
population could be an important source of bias as the influenza vaccination is not independent from 
the pneumococcal vaccination.  Due to small sample size the adjustment for potential confounders 
was not possible and since no information regarding to pneumococcal vaccines (PPSV23 or PCV13) 
was collected for the reference population it was not possible to restrict analysis to those 
unvaccinated with any pneumococcal vaccine.  
Another limitation of the screening method, as used here, is the fact that the vaccine coverage was 
assumed as known. However, it was also obtained from a population sample, so the variance of this 
estimate should be included in the 95% confidence interval VE estimate. Additionally, the chosen 
reference population (community dwellings aged 65 years and more) could not represent the group 
of selected patients. However, using the influenza vaccine coverage achieved in 2015/16 might not 
be an important source of bias as the influenza vaccine coverage in elderly has been around 50% in 
last years, with no significant yearly changes (29).  
Since 2018, an universal vaccination registry replaced local vaccination registries, comprising all 
influenza vaccines inoculated in other places than in public HC. Thus, the error on influenza 
vaccination status on cases, due to the high percentage of elderly vaccinated out of HC that didn´t 
have any vaccine registered, should be lower than previously reported (30). However, as we didn´t 
get access to the information regarding to the site of the vaccination on cases, this error was not 
possible to quantify.  
Given the growing interest on the role of influenza and influenza vaccine on pneumococcal disease, it 
seems necessary to continue to monitor IVE against influenza complications, particularly IPD and PP, 
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to support public health actions. However, we considered that different methods might be used, due 
to the bias that cannot be controlled by using the screening method to measure the IVE against the 
proposed outcomes. 
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ANNEX 1: Selection of pneumococcal pneumonia cases among severe acute respiratory 
infection cases   (11 pages) 
 
1 Background 
The feasibility study performed in Portugal in 2015/16 and 2016/17 seasons to estimate 
pneumococcal conjugated vaccine effectiveness in elderly showed that the primary care setting is 
not a suitable to identify and select pneumonia cases, as elderly population is preferentially attended 
at hospital level (1). Taking advantage of the established hospital network in Portugal to estimate 
influenza vaccine effectiveness (IVE) against hospitalized influenza (2), during the 2017/18 we 
proposed to test all Severe Acute Respiratory Infection (SARI) cases selected for EVA Hospital Study 
for Streptococcus pneumoniae. The pneumococcal pneumonia (PP) selected cases contributed to 
estimate the IVE against pneumococcal pneumonia using the screening method.  
1.1 Objective 
The objective of this study was to assess the feasibility to select PP cases from the SARI cases 
selected for EVA Hospital. 
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2 Methods 
2.1 Study population 
The study population comprised community-dwelling individuals aged 65 years and above with no 
contra-indication for influenza vaccination and hospitalized with SARI in one of the hospitals enrolled 
in EVA Hospital study (Centro Hospitalar Lisboa Central (CHLC)). 
2.1.1 Participating Hospitals 
CHLC is located at Lisbon district and its catchment area has about 362 016 inhabitants (17% of which 
aged 65 more years). For EVA Hospital study, all the internal medicine wards of four hospitals have 
participated in selecting SARI patients. The 10 participating wards had a total of 413 beds (than can 
be upgraded to 458 during contingency periods).  
2.2 Study period 
SARI patients were selected since week 47/2017 to week 17/2018.  
2.3 Outcome of interest 
The outcome of interest was PP in hospitalized patients with SARI and aged 65 years and above.  
PP cases was defined as any SARI hospitalized case that had a thoracic radiography compatible with 
pneumonia and had a positive urinary antigenic test for Streptococcus pneumoniae.  
2.1 Exposure 
The exposure of interest was been vaccination against seasonal influenza within the 2017/18 season. 
2.1.1 Definition of vaccination status and ascertainment 
An individual was considered vaccinated against seasonal influenza if the vaccination occurred more 
than 14 days before SARI symptoms onset. Inoculation with the 2017/18 WHO approved seasonal 
influenza vaccine was ascertained by the health professional, by consultation of the vaccination 
registries. If vaccination registry was not available or individual data were not registered, an 
interview of the patient or his relatives was performed to collect vaccination data. 
2.2 Case selection and sampling 
2.2.1 Definition of SARI patients 
A patient with SARI (3) was defined as an individual with at least one systemic symptom (fever, 
myalgia, malaise, headache and general deterioration) and one respiratory symptom (cough, sore 
throat and shortness of breath) and requiring hospital admission.  
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A hospitalised patient was defined as a patient who was admitted to the participating hospitals and 
hospitalised for at least 24 hours during the study period. 
2.2.2 Inclusion and exclusion criteria  
SARI patients were eligible if they met SARI definition and accepted to participate in the study. 
Written informed consent was collected by the health professional that approached the patient. 
Patients were excluded if they were unable to communicate. Other exclusion criteria were:  
- contraindication for influenza vaccine; 
- SARI onset more than 48 hours after admission at the hospital; 
- institutionalization; 
- influenza vaccine uptake less than 15 days of symptoms onset; 
- previous pneumonia during 30 days previous to symptoms onset. 
 
2.3 Source of information  
Clinical data were collected using a standardised questionnaire filled by the medical doctor at 
hospital ward. Data sources included: 
- hospital medical records and Health Data Platform  
- interview with patient or his/her family 
- vaccination registry 
- hospital and National Institute of Health (INSA) laboratories 
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2.4 Variables collected 
Table 1. Other variables collected 
Variable Definition 
Chronic conditions  diabetes, if treated for insulin-dependent or non-insulin-dependent diabetes; 
 cardiovascular disease (myocardial infarction, angioplasty, coronary artery bypass surgery, 
stroke, transient ischemic attacks, treated hypercholesterolemia, treated hypertension); 
 chronic pulmonary disease (asthma, chronic bronchitis, bronchopulmonary dysplasia, cystic 
fibrosis); 
 invasive pulmonary disease 
 chronic renal diseases (chronic renal failure); 
 rheumatologic disease 
 hematologic cancer 
 Non-hematologic cancer 
 Dementia  
 Stroke 
 Cirrhosis 
 Congenital or Acquired Immunodeficiency (conditions that suppress the immune function due 
to underlying disease and/or therapy – e.g. people receiving chemotherapy, HIV infection); and 
 obesity (IMC>=30) 
 nutritional deficiencies, anaemia. 
Pneumonia Previous pneumonia diagnosis during the 30 days before the symptoms onset. 
Respiratory 
tuberculosis 
Personal history of respiratory tuberculosis. 
Antibiotics  Antibiotics use during the 30 days before the symptoms onset. 
Smoking  Smoking history was collected and coded as follows: never-smoker, former smoker (stopped smoking 
at least one year before inclusion in the study), current smoker. 
Previous vaccinations  Vaccination against seasonal influenza in the current (2017/18) and previous season (2016/17) and 
pneumococcal vaccinations (PPV23 and PCV13) and date of each vaccine uptake 
Demographic 
variables 
 
Sex, date of birth, date of hospital admission 
Notes: PPSV23: pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugated vaccine  
 
2.5 Laboratorial methods 
Urine samples were tested using an immunocromatographic commercial test kit (Alere BinaxNow 
Streptococcus pneumoniae antigen Card) that uses specific polyclonal antibodies against the C-
polysaccharide moiety of Streptococcus pneumoniae for the rapid detection of S. pneumoniae 
antigen in urine, according manufacturers´ instructions. Sensibility and specificity estimates for 
pneumococcal community acquired pneumonia are 75 % and 95 % (4). Samples were tested at 
Hospital or at the National Reference Laboratory. Decision where sample were tested was carried 
out by patient´s medical doctor, accordingly the urgency of the result for the individual case 
management. Samples transportation to the National Reference Laboratory was refrigerated and 
daily performed. Non-urgent results were communicated to patient´s medical doctor within 24 
hours. 
Streptococcus pneumoniae urinary antigen-positive samples were further analysed for the detection 
of 24 serotype-specific pneumococcal antigens (capsular polysaccharides), including those covered 
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by the 13-valent pneumococcal conjugate vaccine (serotypes 1, 2, 3, 4, 5, 6A, 6B, 7B, 8, 9N, 9V, 10A, 
11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), by means of a collaboration established 
between the National Reference Laboratory in Portugal and the Department of Bacterial Surveillance 
and Response, Centre for Infectious Diseases Research, Diagnostics and Screening from the Centre 
for Infectious Diseases Control of the National Institute for Public Health and the Environment in the 
Netherlands (RIVM) . This detection of specific urinary antigens was conducted by RIVM using an in-
house, unpublished, inhibition multiplex immunoassay using the Bioplex technology (Luminex), 
adapted from Elberse et al  (5) to detect at least 10ng/ml of polysaccharide per ml of urine for the 24 
serotypes mentioned above.  
 
 
2.6 Ethical Issues 
The informed consent of 2016/17 EVA Hospital study was adapted for the 2017/18 season to include 
information regarding to the additional data needed.  
The study protocol was approved by the Ethical Committee of the National Institute of Health. 
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3 Results 
 
From 165 patients recruited within EVA Hospital that meet the inclusion criteria, 120 cases 
performed a urinary antigenic test for Streptococcus pneumoniae, which correspond to a 
participation rate of 72.7%. One patient that had a positive hemoculture for Streptococcus 
pneumoniae was also included in the sample, increasing the initial sample to 121 SARI cases. 
Figure 1 represents the selection algorithm followed in respect of the exclusion criteria.  
 
 
                                  
 
Figure 1. Case selection algorithm  
Notes: SARI: severe acute respiratory infection.  
 
Final sample comprised 97 SARI cases and Table 2 presents the description of selected cases. 
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Table 2. SARI and pneumococcal pneumonia cases characteristics 
 
SARI  (n=97) 
   % (IC95%) 
Strept (+) 
10,3 % SARI 
n/N 
PP 
5,7 % SARI 
n/N 
Age (years), mean 80.8 (79.3-82.2) 77.8 77.6 
65-79 years 38.1 (28.9-48.3) 7/10 3/5 
≥80 years 61.9 (51.7-71.1) 3/10 2/5 
Sex, male 35.1 (26.1-45.2) 4/10 2/5 
Smoking 29.5 (21.1-39.6) 5/10 3/5 
Antibiotics 17.7 (11.2-26.8) 2/10 0/5 
Chest radiography 39.3 (29.6-50.0) 5/10 5/5 
≥ 2 chronic conditions 80.4 (71.3-87.2) 6/10 5/5 
Respiratory tuberculosis 10.7 (5.8-19.0) 1/10 0/5 
Influenza  52.6 (42.5-62.5) 5/10 2/5 
Seasonal influenza vaccine (2017/18) 44.7 (35.0-55.0) 2/10 0/5 
PPSV23 3.5 (1.1-10.3) 0/10 0/5 
PCV13 4.7 (1.7-12.1) 1/10 1/5 
Notes: SARI: severe acute respiratory infection; Strept(+): SARI cases that had a positive urinary antigenic test; PP: 
pneumococcal pneumonia; PPSV23: pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugated 
vaccine  
 
 
From the 97 SARI cases, 10 (10.3 %) had a positive test for Streptococcus pneumoniae (urine 
antigenic test or hemoculture) and of those 5 (5.7 % of selected SARI cases) had also a chest 
radiography compatible with pneumonia. 
Both pneumococcal vaccines were less frequent than season influenza vaccine in SARI cases. 
The proportion of SARI cases that had a positive test for Streptococcus pneumonia increased among 
those with chest radiography compatible with pneumonia (14.3%).  
Forty nine urine specimens were sent to the National Reference Laboratory for S. pneumoniae for 
urinary antigen testing, three of which were positive. These three positive specimens were sent to 
RIVM for additional serotyping and all were positive for serotypes 3 and 20. 
Regarding to missing information (Table 3), almost all of collected variables had less than 5 % of 
missing values, except pneumococcal vaccination data.  
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Table 3. Missing data in each collected variable 
Variable n (%) 
Age 0 (0) 
Sex 0 (0) 
≥ 2 chronic conditions 0 (0) 
Smoking 2 (2.1) 
Antibiotics 1 (1.0) 
Pneumonia 3 (3.1) 
Chest radiography 8 (8.2) 
History of personal pulmonary 
tuberculosis 
4 (4.1) 
Influenza 0 (0) 
Seasonal influenza vaccine (2017/18) 1 (1.0) 
PPSV23 9 (9.3) 
PCV13 12 (12.4) 
Date of seasonal influenza vaccine uptake 4 (9.3)* 
Date of PPSV23 uptake 1 (30.0)** 
Date of PCV13 uptake 0 (0) 
* considering the 43 cases vaccinated with seasonal influenza vaccine; ** considering the 3 cases vaccinated with PPSV23 
Notes: PPSV23: pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugated vaccine  
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4 Discussion 
 
The achieved participation rate (72.2%) indicates a high compliance of health professionals and 
patients to collect additional data and samples for this branch of the study. This high acceptance of 
the study by the health professionals might be linked to the importance to better characterize elderly 
SARI patients. In addition, the low resources needed to collect additional data for the study might 
contributed to the high participation rate.  
The quality of collected data is generally good, as the proportion of missing data were below 5% for 
most of the variables. Information regarding to variables newly included in the questionnaire in 
2017/18 season, as having chest radiography compatible with pneumonia, was more prone to be 
missed. This might indicate that the questions were not enough clear or that an additional effort 
should be performed during the validation process.  PPSV23 and PCV13 vaccination data, namely 
date of vaccine uptake, were the variable with higher number of missing values. This is due the 
inexistence of a universal vaccination registry until 2018 and the higher difficult to get accurate 
information from patient or his relatives when compared to seasonal influenza vaccine uptake.  
However, given that a universal vaccination registry is under implementation in Portugal, this 
limitation will be over passed in next few years. 
However, the number of PP cases reached along the season was low and probably underestimate the 
number of hospitalized PP cases in elderly in 2017/18 season. As SARI cases invited to participate in 
EVA hospital represented 46.8 % of all potential selected SARI cases (2), we cannot exclude that a 
selection bias occurred during the SARI selection process if uninvited cases were those who were 
more prone to have a bacterial infection accordingly to the presented clinical presentation.  
Considering the growing need to assess the overall impact of influenza vaccine it seems necessary to 
estimate the influenza vaccine effectiveness against frequent influenza complications, namely 
bacterial pneumonia. In settings where there is no conditions to put in place different studies 
protocols for cases selection, we considered the SARI case definition is appropriate for influenza and 
bacterial pneumonia cases selection as the clinical presentation and data needed to collect can be 
similar and its differential diagnostic part of the individual case management. Thus, it seems 
plausible that increasing the participation rate in EVA Hospital might contribute to increase the 
proportion of PP among SARI cases. The efficacy of case selection could be improved if having a chest 
radiography compatible with pneumonia was added as inclusion criterion for Streptococcus 
pneumoniae testing.  
In this context, testing systematically SARI for influenza and for Streptococcus pneumoniae might 
contribute to increase knowledge regarding SARI aetiology, allowing identify risk factors for bacterial 
pneumonia following influenza. 
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PP cases selected among participating EVA hospital patients were added to the sample of PP 
considering to estimate IVE against PP using the screening method.   
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ANNEX 2: Data Dictionary    (3 pages) 
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Variable name Type Values and coding Definition 
HOSP String  Hospital Centre 
ID Numeric  (count) Id Unique number for patient 
AGE Numeric (count) integer 
 
Age (years)  
AGE_GROUP Numeric (categoric) 1 = <65 years 
2 = 65-79 years 
3 = ≥80 years 
 
SEX Numeric (binary) 0 = female 
1 = male 
Sex of study participant 
ADMISSION Date  dd/mm/yyyy Date of admisson 
SEASON Numeric (categoric) 1 = 2013/14 
2 = 2014/15 
3 = 2015/16 
4 = 2016/17 
5 = 2017/18 
Influenza season 
INST Numeric (binary) 
0 = No 
1 = Yes 
9 = unknown/missing 
Institutionalized 
PNEUMO Numeric (binary) 
0 = No 
1 = Yes 
9 = unknown/missing 
Positive result for St. pneumoniae  
AG Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Urinary antigenic test  
HC Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Hemoculture  
SP Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Sputum test  
LBA Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Bronchoalveolar lavage 
ISCHEMIC Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Ischemic heart disease 
HTA 
Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
High blood pressure 
CI 
Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Cardiac insufficiency 
DIABETES 
Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Diabetes 
 31 
CRD Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Chronic respiratory disease 
includes: asthma, chronic 
bronchitis, emphysema, 
bronchopulmonary dysplasia, 
cystic fibrosis, pneumoconiosis 
and pulmonary fibrosis 
IMUNO Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Immunodeficiency congenital or 
acquired: conditions that suppress 
the immune function due to 
underlying disease and/or 
therapy, e.g. chemotherapy, HIV 
infection 
CANCER Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
 
Cancer 
OTHER_CO String  Other underlying condition 
OBESITY Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Obesity 
CD Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
2 or more chronic conditions 
SMOK Numeric  (binary) 0 = No 
1 = Yes (smoker and 
former smoker) 
9 = unknown/missing 
Tobacco use 
ALC Numeric  (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Alcohol abuse 
FLUVAC Numeric (binary) 0 = No 
1 = Yes (≥15 days) 
2 = Yes (<15 days) 
9 = unknown/missing 
Received seasonal influenza 
vaccine in current season 
FLUVAC_DATE Date dd/mm/yyyy 
9 = unknown/missing 
Uptake date 
PCV13 Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Received PVC 13 
PCV13_ DATE Date dd/mm/yyyy PCV13 uptake date 
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9 = unknown/missing 
PPSV23 Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Received PPSV23 
PPSV23_ DATE Date dd/mm/yyyy 
9 = unknown/missing 
PPSV23 uptake date 
OUT Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Occurred out of influenza seasson 
NOSOCOMIAL Numeric (binary) 0 = No 
1 = Yes 
9 = unknown/missing 
Nosocomial pneumonia 
